FDA tells makers of hormone replacement to add another label warning: dementia
The Food and Drug Administration told makers of hormone replacement therapies Tuesday to add another warning to labels that hormones may increase older women's risk of Alzheimer's or other dementia. This follows a study that women 64 and older are at higher risk of dementia when on estrogen therapy.
Since last year, products containing estrogen and progestin are required to announce warnings that hormone therapy increases the risk of breast cancer, heart attacks and strokes.
Estrogen remains an effective treatment for menopausal symptoms, but the FDA urges women use the lowest possible dose for the shortest amount of time to minimize the risks.